Avadel Pharmaceuticals (AVDL) Cash from Operations: 2009-2024
Historic Cash from Operations for Avadel Pharmaceuticals (AVDL) over the last 16 years, with Dec 2024 value amounting to -$46.9 million.
- Avadel Pharmaceuticals' Cash from Operations rose 31.72% to -$15.4 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$70.3 million, marking a year-over-year increase of 9.06%. This contributed to the annual value of -$46.9 million for FY2024, which is 63.50% up from last year.
- Avadel Pharmaceuticals' Cash from Operations amounted to -$46.9 million in FY2024, which was up 63.50% from -$128.5 million recorded in FY2023.
- Avadel Pharmaceuticals' 5-year Cash from Operations high stood at -$46.9 million for FY2024, and its period low was -$128.5 million during FY2023.
- In the last 3 years, Avadel Pharmaceuticals' Cash from Operations had a median value of -$70.3 million in 2022 and averaged -$81.9 million.
- In the last 5 years, Avadel Pharmaceuticals' Cash from Operations plummeted by 82.79% in 2023 and then skyrocketed by 63.50% in 2024.
- Avadel Pharmaceuticals' Cash from Operations (Yearly) stood at -$48.7 million in 2020, then tumbled by 58.64% to -$77.3 million in 2021, then rose by 9.06% to -$70.3 million in 2022, then crashed by 82.79% to -$128.5 million in 2023, then soared by 63.50% to -$46.9 million in 2024.